152 related articles for article (PubMed ID: 37028260)
1. Phosphodiesterase 5 Inhibitor for Pediatric Pulmonary Arterial Hypertension: A Cost-Utility Analysis.
Buendía JA; Lindarte EF; Guerrero Patiño D
Value Health Reg Issues; 2023 Jul; 36():44-50. PubMed ID: 37028260
[TBL] [Abstract][Full Text] [Related]
2. Ambrisentan for in pediatric pulmonary arterial hypertension: A cost-utility analysis.
Buendía JA; Patiño DG; Lindarte EF
Pediatr Pulmonol; 2023 May; 58(5):1562-1568. PubMed ID: 36797849
[TBL] [Abstract][Full Text] [Related]
3. Cost Effectiveness of First-Line Oral Therapies for Pulmonary Arterial Hypertension: A Modelling Study.
Coyle K; Coyle D; Blouin J; Lee K; Jabr MF; Tran K; Mielniczuk L; Swiston J; Innes M
Pharmacoeconomics; 2016 May; 34(5):509-20. PubMed ID: 26739957
[TBL] [Abstract][Full Text] [Related]
4. Clinical efficacy of tadalafil compared to sildenafil in treatment of moderate to severe canine pulmonary hypertension: a pilot study.
Jaffey JA; Leach SB; Kong LR; Wiggen KE; Bender SB; Reinero CR
J Vet Cardiol; 2019 Aug; 24():7-19. PubMed ID: 31405557
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the therapeutic effects and side effects of tadalafil and sildenafil after surgery in young infants with pulmonary arterial hypertension due to systemic-to-pulmonary shunts.
Sabri MR; Bigdelian H; Hosseinzadeh M; Ahmadi A; Ghaderian M; Shoja M
Cardiol Young; 2017 Nov; 27(9):1686-1693. PubMed ID: 28994364
[TBL] [Abstract][Full Text] [Related]
6. Systematic review and cost-effectiveness of bosentan and sildenafil as therapeutic drugs for pediatric pulmonary arterial hypertension.
Chen T; Chen J; Chen C; Zheng H; Chen Y; Liu M; Zheng B
Pediatr Pulmonol; 2021 Jul; 56(7):2250-2258. PubMed ID: 33856119
[TBL] [Abstract][Full Text] [Related]
7. Risk-benefit considerations when prescribing phosphodiesterase-5 inhibitors in children.
Magee AG; Makhecha S; Bentley S
Expert Opin Drug Saf; 2015 May; 14(5):633-42. PubMed ID: 25746065
[TBL] [Abstract][Full Text] [Related]
8. Oral Tadalafil in Children with Pulmonary Arterial Hypertension.
Shiva A; Shiran M; Rafati M; Zamani H; Babazadeh K; Saeedi M; Ala S
Drug Res (Stuttg); 2016 Jan; 66(1):7-10. PubMed ID: 25611962
[TBL] [Abstract][Full Text] [Related]
9. Plasma Drug Concentrations in Patients with Pulmonary Arterial Hypertension on Combination Treatment.
Grünig E; Ohnesorge J; Benjamin N; Burhenne J; Enderle Y; Egenlauf B; Fischer C; Harutyunova S; Huppertz A; Klose H; Haefeli WE
Respiration; 2017; 94(1):26-37. PubMed ID: 28494463
[TBL] [Abstract][Full Text] [Related]
10. Cost-utility of ambrisentan and bosentan for pediatric pulmonary arterial hypertension.
Buendia JA; Patino DG; Lindarte EF
Expert Rev Pharmacoecon Outcomes Res; 2023; 23(8):967-973. PubMed ID: 37403496
[TBL] [Abstract][Full Text] [Related]
11. Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation.
Chen YF; Jowett S; Barton P; Malottki K; Hyde C; Gibbs JS; Pepke-Zaba J; Fry-Smith A; Roberts J; Moore D
Health Technol Assess; 2009 Oct; 13(49):1-320. PubMed ID: 19863849
[TBL] [Abstract][Full Text] [Related]
12. Initial experience with tadalafil in pediatric pulmonary arterial hypertension.
Takatsuki S; Calderbank M; Ivy DD
Pediatr Cardiol; 2012 Jun; 33(5):683-8. PubMed ID: 22402804
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the therapeutic and side effects of tadalafil and sildenafil in children and adolescents with pulmonary arterial hypertension.
Sabri MR; Beheshtian E
Pediatr Cardiol; 2014 Apr; 35(4):699-704. PubMed ID: 24253611
[TBL] [Abstract][Full Text] [Related]
14. Dual phosphodiesterase type 5 inhibitor therapy for refractory pulmonary arterial hypertension: a pilot study.
Kimura M; Tamura Y; Takei M; Yamamoto T; Ono T; Fujita J; Kataoka M; Kuwana M; Satoh T; Fukuda K
BMC Pulm Med; 2015 May; 15():62. PubMed ID: 25971443
[TBL] [Abstract][Full Text] [Related]
15. Cost-Utility of Continuous Positive Airway Pressure for Respiratory Distress in Preterm Infants in a Middle-Income Country.
Buendía JA; Hernández-Sarmiento R; Rojas Medina JE
Value Health Reg Issues; 2023 May; 35():1-7. PubMed ID: 36657278
[TBL] [Abstract][Full Text] [Related]
16. Safety and long-term efficacy of transition from sildenafil to tadalafil due to side effects in patients with pulmonary arterial hypertension.
Lichtblau M; Harzheim D; Ehlken N; Marra A; Pinado FP; Grünig E; Egenlauf B
Lung; 2015 Feb; 193(1):105-12. PubMed ID: 25318865
[TBL] [Abstract][Full Text] [Related]
17. Phosphodiesterase Type-5 Inhibitor Prescription Patterns in the United States Among Men With Erectile Dysfunction: An Update.
Mulhall JP; Chopra I; Patel D; Hassan TA; Tang WY
J Sex Med; 2020 May; 17(5):941-948. PubMed ID: 32144034
[TBL] [Abstract][Full Text] [Related]
18. Comparative Safety of Drugs Targeting the Nitric Oxide Pathway in Pulmonary Hypertension: A Mixed Approach Combining a Meta-Analysis of Clinical Trials and a Disproportionality Analysis From the World Health Organization Pharmacovigilance Database.
Khouri C; Lepelley M; Roustit M; Montastruc F; Humbert M; Cracowski JL
Chest; 2018 Jul; 154(1):136-147. PubMed ID: 29275134
[TBL] [Abstract][Full Text] [Related]
19. A randomized clinical trial investigating treatment choice in Chinese men receiving sildenafil citrate and tadalafil for treating erectile dysfunction.
Bai WJ; Li HJ; Jin JJ; Xu WP; Sebastian S; Wang XF
Asian J Androl; 2017; 19(4):500-504. PubMed ID: 27101805
[TBL] [Abstract][Full Text] [Related]
20. Safety, tolerability, and efficacy of overnight switching from sildenafil to tadalafil in patients with pulmonary arterial hypertension.
Shapiro S; Traiger G; Hill W; Zhang L; Doran AK
Cardiovasc Ther; 2013 Oct; 31(5):274-9. PubMed ID: 23841794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
